Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of sublingual BOL-DP-o-08 for endometriosis-associated symptoms
MOH_2019-11-13_007487Phase 2Completed
- Sponsor
- BOL Pharma
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BOL-DP-o-08, cannabidiol and dronabinol in endometriosis (2 arms), sponsored by BOL Pharma. Started Jan 2019; status: completed.
02
Drugs
BOL-DP-o-08cannabidioldronabinol
03
Conditions
endometriosis
Beyond the preview
Go deeper on MOH_2019-11-13_007487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-13_007487.